Table 1 Baseline patient characteristics (n = 43)

From: A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer

 

N (%)

Median Age (years, range)

63 (34–82)

Sex

 

  Male

33 (76.7%)

  Female

10 (23.3%)

Previous gastrectomy performed with curative intent

 

  Yes

12 (27.9%)

  No

31 (72.1%)

ECOG performance status

 

  0

26 (60.5%)

  1

17 (39.5%)

Pathology

 

  AWD

2 (4.7%)

  AMD

27 (62.8%)

  APD

13 (30.2%)

  SRC

1 (2.3%)

Metastasized organs

 

  Lymph node

36 (83.7%)

  Liver

21 (48.8%)

  Peritoneum

11 (25.6%)

  Lung

7 (16.3%)

  Bone

3 (7.0%)

  Adrenal gland

1 (2.3%)

HER2 positivity

 

  IHC 3+

30 (69.8%)

  IHC 2+ and SISH + 

13 (30.2%)

Pretreatment PD-L1 status

 

  CPS < 1 (negative)

17 (39.5%)

  CPS ≥ 1 (positive)

21 (48.8%)

  CPS ≥ 10

5 (11.6%)

  Not assessed

5 (11.6%)

Baseline CEAa

 

  <5 ng/mL

15 (34.9%)

  ≥5 ng/mL

28 (65.1%)

Baseline CA 19-9a,b

 

  <34 U/mL

19 (46.3%)

  ≥34 U/mL

22 (53.7%)

EBV positivityc

0 (0%)

Deficient MMRd

0 (0%)

  1. ECOG Eastern Cooperative Oncology Group; AWD adenocarcinoma well differentiated; AMD adenocarcinoma moderately differentiated; APD adenocarcinoma poorly differentiated; SRC signet ring cell; HER2 human epidermal receptor 2; IHC immunohistochemistry; SISH silver in situ hybridization; CPS combined positive score; CEA carcinoembryonic antigen; CA carbohydrate antigen; EBV Epstein–Barr virus; MMR mismatch repair.
  2. aTumor markers are grouped by the upper limit of the normal range.
  3. bData available for 41 of 43 patients.
  4. cEBV positivity was determined based on EBV-encoded small RNA in in situ hybridization.
  5. dDeficient MMR by immunohistochemistry for MLH1, MSH2, PMS2, and MSH6.
Back to article page